Clinical Trials in Pittsburgh

Showing 5021-5040 of 21,047 trials

Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies

NCT06355895

Standard planning constraints for liver SBRT incorporate strict dose-volume limits for normal liver parenchyma to minimize the risk of radiation-induced liver disease. The presence of diurnal and fasting/fed variations in liver volume therefore carry substantial potential for introducing errors into estimates of dose-volume distribution within normal liver tissue, as well as affecting day-to-day setup fidelity and organ alignment for treatment. This prospective study will examine how diurnal and fast-fed variations in liver volume affect treatment planning for abdominal SBRT.

Upper Abdominal Malignancies

University of Pittsburgh17 participantsStarted May 2024

Pittsburgh, Pennsylvania, United States

COMPLETEDPhase 1< 1 mile

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05585034

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.

Head and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamous+6 more

Xencor, Inc.60 participantsStarted Dec 2022

Los Angeles, California, United States • Denver, Colorado, United States • Sarasota, Florida, United States +9 more locations

Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Find Trials by Condition in Pittsburgh

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Hemodynamic-GUIDEd Management of Heart Failure

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.

Testicular Tissue Cryopreservation in the Setting of Gender-Affirming Therapy

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

LimiFlex Clinical Trial for the Treatment of Degenerative Spondylolisthesis With Spinal Stenosis

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Intranasal Oxytocin for the Treatment of Alcohol Use Disorder

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Skeletal Health and Bone Marrow Composition Among Youth

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial